NewGenIvf Group (NIVF) Competitors $1.86 -0.09 (-4.56%) Closing price 09/25/2025 03:51 PM EasternExtended Trading$1.93 +0.07 (+3.71%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NIVF vs. ACON, VSEE, DHAC, BACK, OTRK, BTTX, UPHL, OPGN, ACONW, and AONCShould you be buying NewGenIvf Group stock or one of its competitors? The main competitors of NewGenIvf Group include Aclarion (ACON), VSee Health (VSEE), Digital Health Acquisition (DHAC), IMAC (BACK), Ontrak (OTRK), Better Therapeutics (BTTX), UpHealth (UPHL), OpGen (OPGN), Aclarion (ACONW), and American Oncology Network (AONC). These companies are all part of the "healthcare" industry. NewGenIvf Group vs. Its Competitors Aclarion VSee Health Digital Health Acquisition IMAC Ontrak Better Therapeutics UpHealth OpGen Aclarion American Oncology Network NewGenIvf Group (NASDAQ:NIVF) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Is NIVF or ACON more profitable? NewGenIvf Group has a net margin of 0.00% compared to Aclarion's net margin of -11,238.59%. NewGenIvf Group's return on equity of 0.00% beat Aclarion's return on equity.Company Net Margins Return on Equity Return on Assets NewGenIvf GroupN/A N/A N/A Aclarion -11,238.59%-83.63%-76.55% Do institutionals & insiders hold more shares of NIVF or ACON? 66.2% of NewGenIvf Group shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by insiders. Comparatively, 0.8% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, NIVF or ACON? NewGenIvf Group has higher revenue and earnings than Aclarion. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewGenIvf Group$5.43M0.29-$520KN/AN/AAclarion$50K93.15-$6.99MN/AN/A Which has more volatility & risk, NIVF or ACON? NewGenIvf Group has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Do analysts recommend NIVF or ACON? Aclarion has a consensus target price of $11,758.50, suggesting a potential upside of 146,332.13%. Given Aclarion's stronger consensus rating and higher possible upside, analysts clearly believe Aclarion is more favorable than NewGenIvf Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aclarion 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor NIVF or ACON? In the previous week, Aclarion had 1 more articles in the media than NewGenIvf Group. MarketBeat recorded 2 mentions for Aclarion and 1 mentions for NewGenIvf Group. NewGenIvf Group's average media sentiment score of 1.91 beat Aclarion's score of 1.49 indicating that NewGenIvf Group is being referred to more favorably in the media. Company Overall Sentiment NewGenIvf Group Very Positive Aclarion Positive SummaryNewGenIvf Group beats Aclarion on 8 of the 13 factors compared between the two stocks. Get NewGenIvf Group News Delivered to You Automatically Sign up to receive the latest news and ratings for NIVF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NIVF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NIVF vs. The Competition Export to ExcelMetricNewGenIvf GroupMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.69M$7.68B$5.74B$10.39BDividend YieldN/A2.77%5.75%4.64%P/E RatioN/A71.9875.9526.11Price / Sales0.2936.90546.83124.93Price / CashN/A22.3637.5461.24Price / Book-0.016.6912.666.30Net Income-$520K$245.04M$3.29B$271.03M7 Day Performance-1.01%-2.05%0.25%-0.20%1 Month Performance2.82%-0.29%2.80%5.77%1 Year Performance-99.71%8.66%63.42%27.62% NewGenIvf Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NIVFNewGenIvf GroupN/A$1.86-4.6%N/A-99.7%$1.69M$5.43M0.00N/APositive NewsACONAclarion2.622 of 5 stars$7.98-10.3%$11,758.50+147,342.0%-99.5%$4.63M$50K0.007News CoverageGap DownVSEEVSee Health1.7434 of 5 stars$0.68-3.0%$5.00+639.6%-59.8%$2.43M$10.42M0.00N/ADHACDigital Health AcquisitionN/A$0.64-3.1%N/A-57.8%$2.31MN/A0.002,021High Trading VolumeBACKIMACN/A$0.07-1.3%N/A-94.0%$152K$72.05K0.00180News CoverageOTRKOntrak2.3299 of 5 stars$0.03+30.4%$3.00+9,900.0%-99.0%$127K$10.18M0.00250Gap DownBTTXBetter TherapeuticsN/A$0.00-50.0%N/AN/A$5KN/A0.0040Gap UpUPHLUpHealthN/A$0.00flatN/A-99.5%$4K$130M0.001,750OPGNOpGenN/A$0.00flatN/AN/A$1K$2.67M0.00100Positive NewsACONWAclarionN/A$0.03+0.3%N/A+12.9%$0.00$62.95K0.007News CoverageGap DownAONCAmerican Oncology NetworkN/A$10.64+0.5%N/A+137.0%$0.00$1.34B0.001,520Gap Down Related Companies and Tools Related Companies Aclarion Alternatives VSee Health Alternatives Digital Health Acquisition Alternatives IMAC Alternatives Ontrak Alternatives Better Therapeutics Alternatives UpHealth Alternatives OpGen Alternatives Aclarion Alternatives American Oncology Network Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NIVF) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredChina Targets MAGA In Stealth Trade War TacticsChina is deliberately targeting the economic backbone of conservative America - The very industries that supp...Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewGenIvf Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NewGenIvf Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
